Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!   Twitter
Follow us on Instagram!  Instagram 
Add us to your circle in Google+!

Google+ 

Subscribe to our channel on YouTube!  YouTube  


 

 

Bookmark and Share   Print  

New Funding Opportunities

The Cystic Fibrosis Foundation and Cystic Fibrosis Foundation Therapeutics announce these new funding opportunities for 2015.


Delivery Technologies for CFTR Gene Replacement and Repair

Deadline: July 15, 2015, 5:00 pm (ET)

Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, is soliciting proposals that will develop nucleic acid delivery technologies to support CFTR gene editing and gene therapy. Emphasis will also be given to studies developing vectors and delivery mechanisms to be used with gene repair technologies in cell lines and animal models to support the development of CF therapeutics.

Research Objectives

The objective of this RFA is to fund highly meritorious research projects that will advance our understanding and development of nucleic acid delivery approaches in CF cell lines and animal models to support the development of CFTR gene repair and gene transfer technologies as a CF therapeutics strategy.

CFFT is accepting applications that focus on optimizing delivery agents for overcoming the barriers for delivery to CF cells.

Areas of interest include, but are not limited to:

  1. Novel nucleic acid delivery strategies into CF cells in vitro and in vivo for animal models 
  2. Optimizing the formulation of delivery tools including viral and non-viral vectors 
  3. Screening assays for optimizing and characterizing delivery systems 
  4. Studies for dosing and safety of delivery mechanisms for CF 
  5. Targeting to the airway and non-airway tissues (i.e. gut, pancreas) important in CF 
  6. Understanding and addressing the barriers for nucleic acid delivery into cells relevant to CF

Proposals will be accepted in three categories:

  • Research Grants: Funding of up to $150,000 per year for 2 years, plus eight percent (8%) indirect costs. A limited number of larger awards with strong justification (e.g., for animal models) will be considered for funding up to $250K per year, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Pilot and Feasibility Studies: Funding of up to $75,000 for one year, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Postdoctoral Fellowships: Funding of up to $46,250 for year 1 and $47,930 for year 2. No indirect costs permitted. Open to U.S. citizens and permanent residents only.

Applications will be accepted online at ProposalCENTRAL.

back to top 


Repairing CFTR Genetic Mutations for Research Tools and Therapeutics

Deadline: July 15, 2015, 5:00 pm, (ET)

Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, is soliciting proposals that will exploit gene repair technologies for developing research tools for therapeutic applications. Emphasis will be given to studies that focus on the repair of CFTR mutations that are uniquely amenable to gene editing strategies.

Research Objectives

The objective of this RFA is to fund highly meritorious research projects that will aide in the use of gene repair approaches to correct CFTR mutations. Projects of interest include using gene editing approaches for (1) the development of model systems to support CF basic research including cell lines and animal models and (2) to support the use of gene editing for therapeutics. Proposals that focus on utilizing gene editing strategies as a therapy to address CFTR mutations that are unresponsive to current CFTR modulator drugs are of high priority (e.g. nonsense, frameshift, splice site).

Areas of interest include, but are not limited to:

  1. Factors that control the efficiencies of homology directed repair verses non-homologous end-joining repair processes and methods to manipulate these processes in CF 
  2. Technological advancements of homing nucleases (CRISPR/Cas9, ZFNs, TALENs, meganucleases)
    for targeting and repairing CFTR mutations 
  3. Novel methods for delivering editing enzymes in vitro and/or in vivo 
  4. Biological endpoints and assays for CFTR gene repair 
  5. Tool development using gene editing for generating cell lines and animal models containing CFTR mutations in the native gene context 
  6. Understanding threshold and specificity of CFTR repair for a therapeutic index 
  7. Research supporting the development of CFTR gene repair as a therapeutic strategy

Proposals will be accepted in three categories:

  • Research Grants: Funding of up to $150,000 per year for 2 years, plus eight percent (8%) indirect costs.  A limited number of larger awards with strong justification (e.g., for animal models) will be considered for funding up to $250K per year, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Pilot and Feasibility Studies: Funding of up to $75,000 for one year, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Postdoctoral Fellowships: Funding of up to $46,250 for year 1 and $47,930 for year 2. No indirect costs permitted. Open to U.S. citizens and permanent residents only.

Applications will be accepted online at ProposalCENTRAL

back to top 


Stem Cell Applications for Cystic Fibrosis Therapy

Deadline: August 31, 2015, 5:00 pm (ET)

Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, is soliciting proposals that will that will investigate and promote the utility of peripheral and progenitor stem cells to maintain and restore function of affected tissues in individuals with CF.

Emphasis will be given to studies that expand our basic understanding of stem cell biology and facilitate development of new technologies that could ultimately support the development of CF therapeutics.

Research Objectives

The objective of this RFA is to fund highly meritorious research projects that will advance our understanding and development of stem cell biology in the lung and other tissues affected by CF and to support the development of stem cells as a CF therapeutic strategy.

Areas of interest include, but are not limited to:

  1. Identification and behavior of lung progenitor/stem cell populations 
  2. Standardization of iPSC differentiation and maturation protocols 
  3. iPS cell technologies for gene repair in CF relevant cells and tissues  
  4. Mechanisms of engraftment and homing within the stem cell niche 
  5. Bioinformatic resources for characterizing stem cell populations 
  6. Animal models for progenitor targeting and gene editing 
  7. Lineage manipulation of proximal and distal airway epithelial cells 
  8. Targeting progenitor populations in situ 
  9. Immunomodulatory cell therapy 
  10. Adoptive transfer 
  11. Ex vivo lung engineering

Proposals will be accepted in three categories:

  • Research Grants: Funding of up to $150,000 per year for two years, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Pilot and Feasibility Studies: Funding of up to $75,000 for one year, plus eight percent (8%) indirect costs. Note: This funding announcement is designed to encourage the pursuit of high-risk projects that could benefit from a year of pilot funding. Open to international applicants, U.S. citizens and permanent residents.

  • Postdoctoral Fellowships: Funding of up to $46,250 for year one and $47,930 for year two. Indirect costs not permitted. Open to U.S. citizens and permanent residents only.

Applications will be accepted online at ProposalCENTRAL: https://proposalcentral.altum.com 

back to top 

Updated: 6/15/2015

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.